Selegiline Transdermal System: In the Treatment of Major Depressive DisorderA Viewpoint by J. Alexander Bodkin

被引：0
|
作者：
J. Alexander Bodkin
机构：
[1] Harvard Medical School,Consolidated Department of Psychiatry
来源：
Drugs | 2007年 / 67卷 / 2期
关键词：
D O I：
10.2165/00003495-200767020-00007
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：266 / 266
相关论文
共 50 条
  • [41] Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder
    Minelli, A.
    Magri, C.
    Barbon, A.
    Bonvicini, C.
    Segala, M.
    Congiu, C.
    Bignotti, S.
    Milanesi, E.
    Trabucchi, L.
    Cattane, N.
    Bortolomasi, M.
    Gennarelli, M.
    TRANSLATIONAL PSYCHIATRY, 2015, 5
  • [42] Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder
    A Minelli
    C Magri
    A Barbon
    C Bonvicini
    M Segala
    C Congiu
    S Bignotti
    E Milanesi
    L Trabucchi
    N Cattane
    M Bortolomasi
    M Gennarelli
    Translational Psychiatry, 2015, 5 (12) : e687 - e687
  • [43] Of adenosine and the blues: The adenosinergic system in the pathophysiology and treatment of major depressive disorder
    Gomes, Joana, I
    Farinha-Ferreira, Miguel
    Rei, Nadia
    Goncalves-Ribeiro, Joana
    Ribeiro, Joaquim A.
    Sebastiao, Ana M.
    Vaz, Sandra H.
    PHARMACOLOGICAL RESEARCH, 2021, 163
  • [44] Comparison of effectiveness and side effects of selegiline transdermal system versus oral monoamine oxidase inhibitors and tricyclic antidepressants for treatment-resistant depression
    Kim, Thomas T.
    Xu, Colin
    Amsterdam, Jay D.
    JOURNAL OF AFFECTIVE DISORDERS, 2025, 376 : 47 - 51
  • [45] A TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING DEFERIOXAMINE MESYLATE FOR THE TREATMENT OF BETA-THALASSAEMIA MAJOR
    Hsieh, Chin-Hsiung
    Ku, Yuan-An
    Chiu, Lien-Hua
    Young, Tai-Horng
    Huang, Yi-You
    BIOMEDICAL ENGINEERING-APPLICATIONS BASIS COMMUNICATIONS, 2011, 23 (01): : 29 - 35
  • [46] Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects (vol 46, pg 938, 2006)
    Azzaro
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (10): : 1225 - 1226
  • [47] ECONOMIC EVALUATION OF BREXPIPRAZOLE AS ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN THE MEXICAN NATIONAL HEALTH SYSTEM
    Soto Molina, H.
    Escobar Juarez, Y.
    Frias Gasga, A. E.
    Romero Tapia, C. G.
    Diaz Alvarez, O.
    Campos Ramirez, O.
    Marcos-Olivan, N.
    VALUE IN HEALTH, 2022, 25 (07) : S421 - S421
  • [48] Modulating the serotonin system in the treatment of major depressive disorder (vol 19, pg 54, 2014)
    Morrissette, Debbi Ann
    Stahl, Stephen M.
    CNS SPECTRUMS, 2015, 20 (04) : 452 - 453
  • [49] PCLO rs2522833 modulates HPA system response to antidepressant treatment in major depressive disorder
    Schuhmacher, Anna
    Moessner, Rainald
    Hoefels, Susanne
    Pfeiffer, Ute
    Guttenthaler, Vera
    Wagner, Michael
    Schwab, Sibylle G.
    Maier, Wolfgang
    Zobel, Astrid
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2011, 14 (02): : 237 - 245
  • [50] Comment on Fu, J. and Chen, Y.: The efficacy and safety of 5 mg/d vortioxetine compared to placebo for major depressive disorder: a meta-analysis
    Eduardo C. Humes
    Andre R. Brunoni
    Psychopharmacology, 2017, 234 : 903 - 904
12345